In particular, NGALR expression was shown to be modified in myeloproliferative neoplasm (MPN), colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC), glioma, clear cell renal cell carcinoma (ccRCC), glomerulonephritis, hepatocellular carcinoma (HCC), alcoholic hepatitis, obesity, psoriasis, gastric cancer, endometrial cancer, and many other disorders (Table 3). The gene discussed is SLC22A17; the disease is nonpapillary renal cell carcinoma.